Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) completed independent penetration testing on April 17, 2026, identifying no major vulnerabilities and implementing additional security upgrades ahead of its FDA 510(k) submission.

Upgrades include enhanced encrypted identification tags and firmware safeguards to protect donor data and ensure authorized updates. According to the company, these steps strengthen the 510(k) submission and align the technology with evolving FDA medical device cybersecurity guidance, which the company says could enable U.S. market expansion if FDA clearance is obtained.

Positive

• Penetration testing completed with no major vulnerabilities identified
• Security upgrades implemented including encrypted ID tags and firmware safeguards
• 510(k) submission strengthened by early cybersecurity work aligning with FDA guidance

Negative

• FDA clearance pending, outcome remains uncertain and is required to access U.S. market opportunities

News Market Reaction – INBS

-1.48%

5 alerts

-1.48% Session close to close

+12.7% Peak in 4 min

$5.40M Market Cap

0.1x Rel. Volume

In the Apr 17 session, INBS declined 1.48%, reflecting a mild negative market reaction. Argus tracked a peak move of +12.7% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights another step in INBS’s FDA 510(k) journey, focusing on penetration test...

Analysis

This announcement highlights another step in INBS’s FDA 510(k) journey, focusing on penetration testing and security upgrades that aim to protect donor data and align with evolving medical device cybersecurity expectations. It follows recent clinical, manufacturing, and commercial milestones and sits within a broader push toward U.S. drug screening market entry. Investors may watch for subsequent FDA interactions, completion of remaining studies, and how these translate into commercial adoption.

Historical Context

5 past events · Latest: Apr 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 02	Clinical study progress	Positive	-11.9%	Completion of initial cut-off study and launch of broader 510(k) support studies.
Mar 26	Patent portfolio expansion	Positive	+1.5%	Eighth European patent grant reinforcing fingerprint drug screening IP.
Feb 25	Manufacturing scale-up	Positive	-4.3%	First shipments from new partner, boosting capacity and targeting margin gains.
Feb 24	Commercial partnership	Positive	-2.6%	Bouygues UK rollout across 13 project sites with potential wider expansion.
Feb 12	Earnings and financing	Positive	-6.7%	Record Q2 growth, margin improvement, and completion of $10.0M private placement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent INBS news has often been followed by negative next-day moves despite generally positive operational updates, with only one of the last five releases aligning positively with price.

Recent Company History

Over the last few months, INBS has issued a series of generally positive updates, including record fiscal Q2 revenue of $896,774 with 48% YoY growth and improved gross margin to 49%, new manufacturing partnerships that target ~20 percentage-point margin gains, an eighth European patent, and progress toward an FDA 510(k) submission via clinical and method comparison studies. Despite this, four of the last five news events saw negative 24-hour price reactions, indicating a pattern of weak short-term trading response to constructive milestones.

Key Terms

fda 510(k), penetration testing, encrypted identification tags, firmware, +3 more

7 terms

fda 510(k) regulatory

"as part of its upcoming FDA 510(k) submission."

A FDA 510(k) is a premarket notification a medical device maker files to show a new device is similar enough to an already approved device that it can be marketed without a lengthy review. For investors it matters because a cleared 510(k) offers a faster, lower-cost path to sell a product and reduces regulatory uncertainty—think of it like proving you’re using an approved recipe rather than inventing a brand-new one.

penetration testing technical

"announced the successful completion of penetration testing as part of its upcoming"

Penetration testing is a controlled security check where experts try to break into a company’s computer systems, networks or applications to find weaknesses before real attackers do. For investors it signals how well a company manages cyber risk, potential costs from breaches or compliance failures, and the firmness of operational defenses—think of it as hiring a professional to test all the locks and alarm systems so vulnerabilities can be fixed before they cause damage.

encrypted identification tags technical

"These upgrades include enhanced encrypted identification tags to ensure test integrity"

Encrypted identification tags are small digital markers attached to files, devices, or data records that store identifying information in a scrambled form, readable only with the correct decryption key. For investors they act like a tamper-resistant name tag and tracking trail: they help verify a document or data source is genuine, show where information has traveled, and protect sensitive identities, which reduces the risk of fraud, insider leaks, and regulatory violations.

firmware technical

"and improved firmware safeguards that allow only authorized updates and protect"

Firmware is the built-in software that tells a physical device how to operate, stored in the device’s permanent memory rather than on a removable app. Think of it as the instruction manual glued into a gadget’s brain that controls basic functions and features. Investors care because firmware updates or flaws can change a product’s capabilities, security, repair costs, regulatory compliance and customer satisfaction, all of which can affect sales, margins and company value.

cyber threats technical

"only authorized updates and protect against cyber threats."

Cyber threats are malicious actions by individuals or groups using computers and networks—like hackers, malware, or phishing—aimed at stealing data, disrupting operations, or taking control of systems. For investors, they matter because successful attacks can reduce revenue, increase costs, trigger regulatory penalties, and harm a company’s reputation, much like a burglar who damages a store or steals inventory and leaves customers wary, which can lower a company’s value and raise its risk.

medical device cybersecurity technical

"to meet evolving FDA guidance on medical device cybersecurity."

Protection of networked medical equipment and software from hacking, unauthorized access, and malfunction that could alter device behavior, steal patient data, or disrupt clinical care; think of it as locks, alarms and regular maintenance for connected hospital gear. Investors care because weak cybersecurity can lead to costly recalls, regulatory penalties, lawsuits, service downtime and damage to a company’s reputation, all of which can reduce revenues, increase expenses and raise long-term risk.

fda clearance regulatory

"If obtained, FDA clearance will open new revenue and expansion opportunities"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company's existing security infrastructure, and strengthened its regulatory submission to the FDA.

In conjunction with the penetration testing, INBS implemented additional security upgrades to its drug testing technology. These upgrades include enhanced encrypted identification tags to ensure test integrity and improved firmware safeguards that allow only authorized updates and protect against cyber threats.

"Successful completion of penetration testing is another key milestone in our FDA 510(k) submission process. This independent assessment identified no major security vulnerabilities, confirming the effectiveness of our security approach,” said Harry Simeonidis, President and CEO at INBS. “These new upgrades reflect our commitment to protecting donor data and implementing security measures that meet and exceed regulatory expectations, bolstering our upcoming 510(k) submission to the FDA."

The penetration testing forms part of INBS's FDA 510(k) submission. By addressing security requirements early in the process, INBS is positioning its technology to meet evolving FDA guidance on medical device cybersecurity. If obtained, FDA clearance will open new revenue and expansion opportunities for the Company in the multi-billion-dollar U.S. drug screening market.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. 

For more information, visit: https://ibs.inc/

Forward-Looking Statements 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  

Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

FAQ

What did Intelligent Bio Solutions announce on April 17, 2026 about its FDA 510(k) submission (INBS)?

They completed penetration testing with no major vulnerabilities, strengthening their 510(k) submission. According to the company, additional security upgrades and firmware safeguards were implemented to protect donor data and test integrity ahead of the submission.

How do the new security upgrades affect INBS's drug testing technology and data protection?

The upgrades add encrypted identification tags and firmware safeguards to the technology. According to the company, these measures ensure test integrity, permit only authorized updates, and reduce cyber-risk exposure in device operation and data handling.

Does the successful penetration testing guarantee FDA clearance for INBS (INBS)?

No — successful testing improves the submission but does not guarantee clearance. According to the company, this independent assessment bolsters the 510(k) package but final FDA determination is still required.

What potential market impact did Intelligent Bio Solutions describe for INBS if FDA clearance is obtained?

If cleared, the company expects access to the multi-billion-dollar U.S. drug screening market. According to the company, FDA clearance would open new revenue and expansion opportunities for its rapid, non-invasive testing solutions.